This study explores a novel therapeutic strategy for pleural mesothelioma, a highly aggressive cancer with limited treatment options. The researchers investigated the combined inhibition of VEGFR2, a key regulator of angiogenesis, and PD-L1, an immune checkpoint protein, in preclinical mouse models of mesothelioma. They found that this dual-targeting approach significantly improved survival, reduced tumor growth, and normalized tumor vasculature compared to single-agent treatments.
To evaluate vascular changes, the researchers used the IKOSA Network Formation Assay, which enabled automated and objective analysis of vessel branching, loop formation, and thickness, providing robust evidence for the normalization effect.
The results highlight the potential of combining anti-angiogenic therapy with immune checkpoint inhibition as a promising approach for mesothelioma treatment. Moreover, the study showcases the value of advanced image analysis platforms like IKOSA in generating quantitative insights from complex biological data.
View the full article in the journal and see how IKOSA supported the research